Breast Cancer Clinical Trial
Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer
This clinical trial evaluates the feasibility and acceptability of a mobile health device in improving oral chemotherapy adherence in women with triple negative breast cancer that has not spread to other places in the body (non-metastatic). A mobile health device, called SMRxT smart pill bottle may help doctors to remind patients to take medicine on time and monitor their symptoms.
I. Feasibility. II. Acceptability. III. Capecitabine/Xeloda adherence.
I. Symptom burden. II. Patent physician communication. III. Quality of life. IV. Self-efficacy for managing symptoms.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive a SMRxT smart pill bottle, report symptoms weekly, and receive reminders for missing or incorrect dose for standard of care 3-week capecitabine/Xeloda treatment cycles.
GROUP II: Patients receive standard of care.
After completion of study, patients are followed up for 90 days after the initiation of capecitabine/Xeloda.
Age >= 18 years
New or existing prescription for capecitabine/Xeloda who get it filled at the Emory Specialty Pharmacy (within the first 3 cycles of use)
Willingness and ability of the subject to comply with study procedures
Have a mobile phone with text message
Evidence of an online informed consent indicating that the subject is aware of the risk and benefits of study participation
Those who do not receive their capecitabine/Xeloda prescription until a month after enrollment
Eastern Cooperative Oncology Group (ECOG) performance status > 2
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.